Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS
Reuters
Aug 28
Redwire Corporation Secures $25 Million NASA Contract for Biotechnology Support on ISS
Redwire Corporation has been awarded a NASA single award, indefinite-delivery/indefinite-quantity (IDIQ) contract with a ceiling of $25 million over a five-year period. This contract enables Redwire to fulfill future task orders for biotechnology facilities, on-orbit operations support, mission integration, and related services aboard the International Space Station (ISS). Recently, a $2.5 million task order was issued to Redwire under NASA's In Space Production Applications (InSPA) program to aid in drug development investigations using Redwire's PIL-BOX technology. As a global leader in microgravity research and development technologies, Redwire is set to manage and facilitate experiments and support on-orbit operations for NASA-funded research. The company's biotechnology facilities play a crucial role in NASA's ISS research strategy, expanding on-orbit capabilities in fields such as drug development, cancer research, and tissue engineering.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redwire Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250828913799) on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.